We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00213122
First Posted: September 21, 2005
Last Update Posted: September 28, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
  Purpose
In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: miglitol Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • type2 diabetes
  • postprandial plasma glucose levels ≧180mg/dl

Exclusion Criteria:

  • type1 diabetes
  • AST(GOT) or ALT(GPT) ≧100IU/l
  • creatinine ≧2.0mg/dl
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213122


Locations
Japan
Ibaraki, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Investigators
Study Director: Clinical Promotiom Group Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

ClinicalTrials.gov Identifier: NCT00213122     History of Changes
Other Study ID Numbers: MG1007
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: September 28, 2006
Last Verified: September 2006

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Miglitol
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors